View More

CUVIS-spine Launches Full-Scale Clinical Surgeries Under Korea's Innovative Medical Technology Program

•  Adoption continues to grow at major medical centers, including Kangnam Sacred Heart Hospital and Yongin Severance Hospital, as efforts advance toward future National Health Insurance coverageCUREXO, a medical robotics company, announced on June 16 that the multicenter clinical study for evidence generation under Korea's Innovative Medical Technology Program using its robotic spine surgery system, CUVIS-spine, has officially begun at Chung-Ang University Hospital and Pusan National University Yangsan Hospital.Designated as an Innovative Medical Technology by the Ministry of Health and Welfare, CUVIS-spine is currently being evaluated through multicenter clinical studies at leading medical institutions across Korea. The recent procedures performed at Chung-Ang University Hospital and Pusan National University Yangsan Hospital represent clinical applications of the technology within the study and are expected to further expand real-world experience and clinical data from actual surgical settings.CUVIS-spine is a robotic spine surgery system that provides precise guidance for spinal implant placement through preoperative image-based planning and real-time tracking technology. By combining robotic accuracy with conventional surgical approaches that have traditionally relied heavily on physician experience, the system helps reduce surgical variability and maximize patient safety.In addition, through its collaboration with CG Bio, CUVIS-spine is expanding its presence in both domestic and international spine surgery markets. The company is also strengthening its competitiveness in the field by building a robot-navigation-based spine surgery platform.CUREXO has been accumulating real-world clinical cases at participating institutions in the Innovative Medical Technology Program, including Yonsei Severance Hospital, Chung-Ang University Hospital, and Pusan National University Yangsan Hospital. Adoption of CUVIS-spine is also expanding to other major healthcare institutions, including Kangnam Sacred Heart Hospital and Yongin Severance Hospital. A CUREXO representative stated, "With Innovative Medical Technology procedures now being performed at Chung-Ang University Hospital and Pusan National University Yangsan Hospital, the number of real-world clinical applications of CUVIS-spine continues to increase. Based on the clinical experience being accumulated across various medical institutions, we will continue working to establish the foundation for reimbursement, including National Health Insurance coverage, while contributing to the advancement of spine surgery in Korea."

View More

MorningWalk Showcases Clinical Success at JARM 2026

•  Clinical Benefits of 'Propulsion Feedback Training' Using an End-Effector Gait Rehabilitation Robot RevealedCUREXO, a medical robotics company, announced on June 4 that it will present the latest clinical outcomes using its next-generation gait rehabilitation robot, MorningWalk, at the 63rd Annual Scientific Meeting of the Japanese Association of Rehabilitation Medicine (JARM 2026), which will be held from June 4 to 7 at the Fukuoka Convention Center in Japan.MorningWalk gait rehabilitation robot system. (Image: CUREXO)The JARM Annual Meeting is one of the largest academic events in Japan dedicated to rehabilitation medicine, bringing together rehabilitation specialists from Japan, across Asia, and around the world to share the latest research findings and clinical experiences.At this year's conference, CUREXO will present research under the theme, "Effects of Propulsion Feedback Training Using a Novel End-Effector Gait Rehabilitation Robot."MorningWalk is a footplate-based end-effector gait rehabilitation robot. Unlike exoskeleton-type systems that require the robot to be directly attached to the patient's body, it offers shorter setup times and enables a variety of gait training patterns.In particular, the propulsion feedback training technology featured in this presentation allows patients to recognize and adjust the force used to push off the ground during walking in real time, enabling more active gait training.A CUREXO representative said, "This presentation is a meaningful opportunity to introduce MorningWalk's clinical effectiveness and technological competitiveness to rehabilitation medicine experts worldwide. We plan to actively expand our gait rehabilitation robotics business in overseas markets, including Japan, and strengthen global partnerships."

View More

CUVIS-spine Surgical Robot Receives Medical Device Approval in Mexico

CUREXO, a medical robotics company (CEO: Lee Jae-jun), announced on the 27th that its spine surgery robot, "CUVIS-spine," has received medical device approval from Mexico's regulatory authority, COFEPRIS.[Photo = CUREXO] CUVIS-spine Surgical Robot SystemMexico, with a population of approximately 130 million, is ranked among the world's top 10 most populous countries and is considered the second-largest medical device market in Latin America. Driven by a growing aging population and expanding healthcare infrastructure, demand for medical devices continues to increase, positioning Mexico as a strategic gateway market in the Latin American region.CUREXO plans to accelerate local sales and marketing activities for CUVIS-spine in collaboration with ARTIMEDICA, a specialized medical device company in Mexico.CUVIS-spine is a robotic system designed to enhance the precision of spinal surgeries through advanced surgical planning and precise navigation capabilities. Utilizing real-time tracking technology during procedures, the system guides accurate screw placement according to the preoperative plan while reducing radiation exposure for both patients and medical staff, thereby improving both safety and convenience. A representative from CUREXO stated, "Based on this medical device approval in Mexico, we plan to strengthen cooperation with our local partner to actively expand into the Mexican market and further broaden the supply of medical robotic systems throughout Latin America."

View More

CUREXO, Secures Surgical Robot Supply Deal in Paraguay

• Accelerates Expansion into Latin American Market and Strengthens Global Medical Robot Supply Network CUREXO, a medical robotics company led by CEO Lee Jae-jun, announced on May 19 that it has signed a contract to supply its orthopedic surgical robot, CUVIS-joint, to Paraguay.The agreement was signed with Droguepar S.A, a medical device company in Paraguay. Through this contract, CUREXO plans to accelerate its entry into the Latin American medical robotics market.CUVIS-joint analyzes a patient's CT scans in 3D prior to surgery to establish an optimized surgical plan. During surgery, the robot arm precisely cuts bone, maximizing surgical accuracy while minimizing side effects.Last year, CUREXO supplied medical robots to Latin American countries including Brazil, laying the groundwork for expansion in the region. With the Paraguay agreement, the company intends to further strengthen its network across the Latin American market. According to the company, it also plans to expand into major regional markets such as Mexico in the future. A CUREXO official stated, "This agreement represents a meaningful achievement in expanding our presence in the Latin American market," adding, "Based on close cooperation with our local partner, we will continue to strengthen our competitiveness in the global medical robotics market."

View More

CUREXO Signs Strategic Partnership with Italian Implant Manufacturer Permedica

•  Expanding supply across Italy and North Africa•  Anticipating synergies with global implant companies through an open-platform strategy CUREXO Inc., a medical robotics specialist, announced on the 30th that it has entered into a distribution agreement with Permedica S.p.A., an Italian orthopedic medical device company, for the supply and sales of its surgical robots in Italy and Morocco. [Photo = CUREXO] Jean Cho, Head of Overseas Sales at CUREXO (left), and Federico Diego Perego, CEO of Permedica (right), pose for a commemorative photo following the signing ceremony. Under the agreement, CUREXO will supply its robotic joint replacement system, CUVIS-joint, to Italy and the broader North Africa (MENA) region through Permedica's distribution network. Founded in 1986, Permedica is an Italian orthopedic implant company that operates across multiple countries through its global sales network, offering a wide range of orthopedic medical devices. The two companies recently demonstrated robotic-assisted surgery at the Mohammed VI Foundation for Sciences and Health (FM6SS) in Morocco, showcasing the synergy between CUVIS-joint's precise bone-cutting technology and Permedica's premium implant solutions. The company noted that the successful surgical demonstration attracted strong interest from local medical professionals and stakeholders. CUVIS-joint is an open-platform robotic system for joint replacement surgery, compatible with implants from multiple manufacturers. Collaboration with Permedica's implant portfolio is expected to accelerate market expansion across Europe. A CUREXO representative stated, "Through our partnership with Permedica, we have strengthened our foundation for entering the European and North African markets. We plan to accelerate our penetration of the global medical robotics market through close collaboration with local partners." Meanwhile, CUREXO continues to expand its global footprint, having obtained U.S. FDA clearance and European CE MDR certification.

View More

CUREXO Participates in Korea–India Business Partnership Forum

•  Participation in Korea–India Business Partnership Forum… Strengthening Local Network Based on Indian Subsidiary[Photo = Curexo] Curexo CEO Jaejun Lee (left) is explaining the artificial joint surgery robot to Minister of Trade, Industry and Energy Jeong-kwan Kim (right) at the Korea–India Business Forum.CUREXO, a medical robotics company (CEO Jaejun Lee), announced that it participated in the Korea–India Business Partnership Forum held in New Delhi, India, on the 21st, as part of its efforts to expand its local network and target the Indian medical robotics market. The event was organized by the Korea Trade-Investment Promotion Agency (KOTRA) as an economic cooperation program aligned with the bilateral summit schedule between Korea and India. Various business programs, including a signing ceremony for achievements and showcases, were held for Korean companies operating in the local market. CUREXO was invited to participate in the event as a representative advanced medical device company from Korea operating in India. During the forum, CEO Jaejun Lee met with key domestic and international stakeholders, including Minister of Trade, Industry and Energy Jeong-kwan Kim, and introduced the technological capabilities and global market achievements of the company's flagship product, the artificial joint surgery robot "CUVIS-joint." Since establishing its local subsidiary in India last year, CUREXO has been accelerating its entry into the local market and expanding cooperation with Indian medical institutions and partners, centered on its artificial joint surgery robot "CUVIS-joint." Jaejun Lee, CEO of CUREXO, stated, "India is one of the key markets with high growth potential in the global medical robotics sector," adding, "Through this forum, we will strengthen our local partnership network and further solidify our position in the global medical robotics market."

View More

CUVIS-spine Advances to Multicenter Trials as Innovative Medical Technology

CUREXO Inc. (CEO: Jaejun Lee), a medical robotics company, announced on March 27 that its spinal surgery robotic system, CUVIS-spine, has officially entered multicenter clinical trials under the Innovative Medical Technology designation. The Innovative Medical Technology program is designed to support the early adoption of new medical technologies by allowing their use in clinical settings for a limited period while verifying safety and efficacy. Technologies validated through this process may subsequently qualify for institutional adoption, including reimbursement under the national health insurance system. For this clinical study, CUREXO has completed Institutional Review Board (IRB) submissions across multiple major hospitals, including Yonsei University Severance Hospital (Sinchon), Pusan National University Yangsan Hospital, Chung-Ang University Hospital, Kangnam Sacred Heart Hospital, and Yongin Severance Hospital. All participating institutions are currently undergoing review. The company aims to complete clinical cases within the year and plans to pursue a step-by-step strategy toward broader adoption, including national health insurance reimbursement, following the completion of the multicenter trials. Notably, Professor Dong-Wook Sohn's research team at Pusan National University Yangsan Hospital, a key participating institution, was recognized for its academic excellence in the January 2026 issue of the Journal of Korean Neurosurgical Society (JKNS), where its study was selected as one of the "Most Influential Spine Research (2023–2024)." The participation of this highly regarded research team is expected to further enhance the credibility of the upcoming clinical outcomes. CUVIS-spine is a next-generation robotic system that supports precise screw placement and surgical planning in spinal procedures, contributing to improved surgical accuracy and enhanced patient safety. CUREXO has also recently accelerated its domestic market expansion by signing an exclusive distribution agreement in Korea with CGBIO Co., Ltd., a company specializing in bio-regenerative medicine, for the CUVIS-spine system. The company has already completed its first domestic installation, generating initial commercial results. Building on this milestone, both companies plan to strengthen system competitiveness through collaboration, incorporating clinical data and real-world feedback. A company official stated, "The entry of CUVIS-spine into multicenter clinical trials marks a significant milestone in demonstrating both its technological capabilities and clinical effectiveness. Following the completion of the trials within the year, we will actively pursue broader market adoption alongside establishing institutional pathways such as insurance coverage."

View More

CUVIS-joint Surgical Robot Secures U.S. FDA Approval

•  CUVIS-joint Surgical Robot Secures U.S. FDA Approval, Targeting $14.4 Billion North American Market CUREXO Inc. (KOSDAQ: 060280), a medical robotics company, announced on March 26 that its robotic system for joint replacement surgery, CUVIS-joint, has received approval from the U.S. Food and Drug Administration (FDA). The company obtained FDA clearance approximately nine months after submitting its application in July 2025, marking a significant milestone in its entry into the United States, the world's largest medical device market. The North American joint replacement market is valued at approximately USD 14.4 billion (KRW 19 trillion), accounting for over 60% of the global market. In the United States alone, more than 4.3 million joint replacement procedures are performed annually across over 1,400 hospitals, providing a stable demand base and accelerating the adoption of surgical robotics. CUVIS-joint is a fully automated robotic system designed to assist surgeons in precisely cutting bone and accurately implanting prosthetic joints based on preoperative imaging data. Built on an open-platform architecture, the system is compatible with a wide range of implants and enables patient-specific procedures, improving both surgical accuracy and efficiency. Since receiving approval from Korea's Ministry of Food and Drug Safety (MFDS) in June 2020, CUVIS-joint has continued to demonstrate its technological competitiveness in major global markets, securing regulatory approvals from Japan's PMDA in 2025 and the European CE MDR certification in 2026. Currently, CUVIS-joint is in use across more than nine countries, including India, Indonesia, Taiwan, Japan, Brazil, and Vietnam, with cumulative procedures reaching approximately 43,000 cases. Building on this global track record, the company expects to strengthen its competitiveness in the U.S. surgical robotics market, which is led by major global ps. A company official stated, "This FDA approval is particularly meaningful as it marks our entry into the United States, the world's largest medical device market. Leveraging our extensive global references and fully automated technology, we will focus on translating this milestone into tangible revenue growth in the U.S. market."

View More

Showing a Leading Lineup of Three Surgical Robots at KIMES 2026

SEOUL, South Korea, March 23, 2026 – CUREXO (CEO Jae-jun Lee), a leading medical robotics specialist, announced its successful participation in the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026), held at COEX in Seoul through March 22.At this year's exhibition, CUREXO introduced its latest medical robotics portfolio, covering the entire patient care continuum from surgical intervention to recovery. Key highlights included:•  CUVIS-joint: Featured the upgraded "Knee 2.0" version for total knee arthroplasty and new Total Hip Arthroplasty (THA) capabilities.•  CUVIS-spine: Demonstrated its new endoscopic navigation functionality for enhanced surgical precision.•  Morning Walk: Showcased a newly developed gait propulsion training system for advanced lower-limb rehabilitation.Innovative Solutions for Precision SurgeryCUVIS-joint is an AI-driven surgical system that enhances accuracy through robotic control and provides patient-specific joint replacement via its open-platform compatibility. With extensive clinical data from both domestic and international markets, the system has solidified its competitive edge through proven safety and operational efficiency.CUVIS-spine is designed to provide precise guidance for pedicle screw placement during spinal surgery, minimizing errors and reducing the physical burden on surgical teams. It is gaining traction in the field for its high accuracy, particularly in minimally invasive surgery (MIS) environments.Advancing Rehabilitation TechnologyFor patients with lower-limb paralysis or gait impairments, MorningWalk—an end-effector type gait rehabilitation robot—provides repetitive and precise training to facilitate faster recovery."Through KIMES 2026, we successfully demonstrated CUREXO's technological leadership in both surgical and rehabilitative robotics to medical professionals and industry leaders," said a CUREXO representative. "By leveraging our end-to-end portfolio that spans from orthopedic surgery to rehab, we will continue to strengthen our position as Korea's representative medical robotics company."